Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

NCT03080805 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Metastatic Breast Cancer

Interventions

DRUG: Pyrotinib Plus Capecitabine
DRUG: Lapatinib Plus Capecitabine

Sponsor

Jiangsu HengRui Medicine Co., Ltd.